Document Detail


Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.
MedLine Citation:
PMID:  20535513     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
We reported a post-marketing experience of 190 patients affected by relapsing multiple sclerosis on treatment with natalizumab. Clinical findings during pre-treatment period and throughout the study were documented. Magnetic resonance imaging (MRI) scans were performed at baseline and at 6, 12, and 24 months of therapy. Cumulative proportions of patients disease activity free (i.e. absence of relapses, disability progression, MRI activity) were measured as efficacy endpoints. Despite that the baseline characteristics suggested a more severe course of disease in our sample than that of the AFFIRM trial, data on effectiveness of natalizumab were comparable. At 1 year of treatment we found 80 and 70% patients free from relapses and MRI activity, respectively, that is similar to 75 and 62% detected in the AFFIRM trial. Moreover, only 5% of our patients showed a progression of disability after a mean follow-up time of 15 months. Finally, the presence of antibodies anti-Natalizumab was strongly related to the occurrence of relapses (p = 0.002) and MRI activity (p < 0.001) even in the post-marketing experience.
Authors:
L Prosperini; G Borriello; F Fubelli; F Marinelli; Carlo Pozzilli
Related Documents :
3429733 - Lateralization of dichotic noise bursts: effect of onset and offset disparity.
17686363 - Retrobulbar acute optic neuritis.
18280613 - Efficacy of pet/ct in the characterization of solid or partly solid solitary pulmonary ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology     Volume:  31 Suppl 3     ISSN:  1590-3478     ISO Abbreviation:  Neurol. Sci.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-02-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959175     Medline TA:  Neurol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  303-7     Citation Subset:  IM    
Affiliation:
Multiple Sclerosis Centre, S. Andrea Hospital, "La Sapienza" University, Via di Grottarossa 1035, 00189, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Natalizumab efficacy on cognitive impairment in MS.
Next Document:  Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis:...